VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Increase in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 112,300 shares, an increase of 82.9% from the December 31st total of 61,400 shares. Based on an average trading volume of 118,200 shares, the short-interest ratio is presently 1.0 days. Approximately 0.9% of the company’s shares are short sold.

Insider Transactions at VYNE Therapeutics

In related news, Director Patrick G. Lepore bought 15,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was bought at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the transaction, the director now directly owns 51,472 shares in the company, valued at $150,298.24. This represents a 41.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.80% of the stock is currently owned by insiders.

VYNE Therapeutics Price Performance

NASDAQ:VYNE traded down $0.01 during midday trading on Friday, reaching $2.35. The stock had a trading volume of 105,508 shares, compared to its average volume of 125,502. The stock has a market capitalization of $34.66 million, a P/E ratio of -2.73 and a beta of 1.30. VYNE Therapeutics has a 1-year low of $1.57 and a 1-year high of $4.30. The firm’s fifty day simple moving average is $2.90 and its 200-day simple moving average is $2.41.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.11 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. On average, equities research analysts anticipate that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on VYNE shares. HC Wainwright restated a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a report on Tuesday, January 14th. BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 target price for the company.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.